|
HS Code |
224668 |
| Chemical Formula | C4H3Cl2NS |
| Molecular Weight | 168.04 |
| Appearance | Typically a solid or viscous liquid |
| Melting Point | Data varies, specific value needed from more detailed sources |
| Boiling Point | Data varies, specific value needed from more detailed sources |
| Solubility In Water | Low solubility |
| Solubility In Organic Solvents | Soluble in some organic solvents like dichloromethane |
| Density | Data varies, specific value needed from more detailed sources |
| Odor | May have a pungent or characteristic odor |
| Stability | Should be stored properly to avoid decomposition, reacts with strong oxidizing agents |
As an accredited 2-Chloro-5-Chloromethylthiazole factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 2 - Chloro - 5 - Chloromethylthiazole: Packed in 1 - kg bottles for chemical storage. |
| Shipping | 2 - Chloro - 5 - chloromethylthiazole is shipped in well - sealed, corrosion - resistant containers. Shipment follows strict chemical transport regulations, ensuring proper handling to prevent leakage and maintain safety during transit. |
| Storage | 2 - Chloro - 5 - chloromethylthiazole should be stored in a cool, dry, well - ventilated area. Keep it away from sources of heat, ignition, and incompatible substances such as strong oxidizing agents. Store in a tightly - sealed container to prevent leakage and exposure to air and moisture, which could potentially cause decomposition or reactivity issues. |
What Drives the Demand for 2‑Chloro‑5‑Chloromethylthiazole in Neonicotinoid Insecticide Synthesis?The primary commercial consumption of 2‑Chloro‑5‑Chloromethylthiazole (CCMT) occurs in the condensation step that builds the thiazole ring of thiamethoxam, a second‑generation neonicotinoid active ingredient. On production‑scale equipment—typically 6,300‑litre glass‑lined reactors (DIN 28090‑1 compliant, Pfaudler‑type with retreat‑curve impeller agitation 60–80 rpm)—CCMT is fed as a solution in anhydrous dichloromethane or toluene to a pre‑cooled slurry of 3‑methyl‑4‑nitroimino‑1,3,5‑oxadiazine (MNOA). The molar ratio of CCMT to MNOA is maintained between 1.0 : 1.05 and 1.0 : 1.10, with the slight excess offsetting the competitive hydrolysis of the chloromethyl group. Reaction temperature is held at 45–55 °C for 6–8 hours under a nitrogen blanket; endpoint is determined by HPLC (C18 column, acetonitrile‑phosphate buffer pH 3.0, UV 254 nm) when residual MNOA falls below 0.5 area‑%. Once the condensation is complete, the reaction mass is washed with demineralized water at 35–40 °C to remove triethylamine hydrochloride, and the organic phase is concentrated under vacuum (–0.085 to –0.092 MPa) until a thick slurry forms. Crystallization is induced by adding n‑heptane under controlled cooling (0.2 °C/min to 10 °C), followed by centrifugation in a horizontal peeler centrifuge (900 rpm, cloth pore size 10 µm) and double‑cone vacuum drying at 50 °C for 12 hours. The yield of isolated technical thiamethoxam typically ranges between 88 % and 92 % (on CCMT basis), with the main process‑related impurity being a dimeric thioether formed when the chloromethyl group reacts with trace thiolate generated from thiazole ring degradation. This side reaction accelerates sharply when the moisture content of the solvent exceeds 200 ppm, making on‑line Karl Fischer monitoring (METTLER TOLEDO C30S) a critical process control. The dried product is milled in a pin mill (5,000 rpm) to a particle size D90 ≤ 15 µm and must comply with FAO Specification 277/TC (April 2020 revision), which mandates a thiamethoxam content of ≥ 950 g/kg, water content ≤ 10 g/kg, and acetone‑insoluble matter ≤ 2 g/kg. Additional compliance markers include ISO 17034:2016 for reference material characterization, EPA 40 CFR § 180.920 residue tolerances for use on corn seed treatment, and the CIPAC 1C method for particle size analysis. The final technical concentrate is formulated downstream into water‑dispersible granules (WG, using fluid‑bed agglomeration at an inlet temperature of 70 °C), suspension concentrates (SC, wet‑milled with 0.6–0.8 mm zirconia beads), and flowable concentrates for seed treatment (FS), all regulated under FAO/WHO Joint Meeting on Pesticide Specifications (JMPS) evaluation procedures.
Industrial production of clothianidin exploits the electrophilic chloromethyl handle of CCMT in a two‑step sequence that first builds the N‑methylaminomethyl side chain and then engages a nitroenamine synthon to close the guanidine‑type pharmacophore. In a dedicated 3,000‑litre stainless‑steel reactor (SS316L, electropolished to Ra ≤ 0.4 µm), CCMT is dissolved in anhydrous tetrahydrofuran and cooled to 0–5 °C. Aqueous monomethylamine (40 % w/w, 1.15–1.25 molar equivalents) is added dropwise over 4 hours while maintaining the jacket temperature at –5 °C; the exotherm is managed by a cascade loop linking jacket inlet temperature to reaction mass temperature with a 2 °C deadband. After TLC monitoring confirms complete conversion, the mixture is warmed to 20 °C and the THF is stripped under reduced pressure (150 mbar). The resulting crude 2‑chloro‑5‑(N‑methylaminomethyl)thiazole is immediately taken into methanol and treated with 1,1‑dimethoxy‑N‑methyl‑2‑nitroethenamine (1.05 equivalents). The suspension is refluxed (65 °C) for 10–12 hours while methanol is slowly distilled to drive the transamination and ring closure. The product crystallizes spontaneously upon cooling; it is isolated via a filter‑dryer combination (Cogeim Nutsche, PTFE membrane 5 µm) and washed with ice‑cold methanol. The Clothianidin technical concentrate is dried at 45 °C for 18 hours until loss‑on‑drying (IR balance, 105 °C) reaches ≤ 0.5 %. The isolated yield falls between 82 % and 87 %, strongly dependent on the exclusion of CO₂ during amination, which otherwise forms carbamate side products. The final TC must meet FAO Specification 738/TC (October 2021), requiring a clothianidin content ≥ 970 g/kg and a water‑insoluble matter limit of ≤ 3 g/kg, as assessed by CIPAC MT 15. Environmental compliance follows US EPA 40 CFR § 180.586 for seed treatment residues and EU Regulation 283/2013 under active substance renewal. The downstream formulated product is predominantly a flowable concentrate for seed treatment (FS) wherein the micronized TC (D50 1.5–2.5 µm by laser diffraction, ISO 13320:2020) is suspended with polymeric dispersants and pigment‑grade iron oxide in a high‑shear rotor‑stator mixer (Ika Ultra‑Turrax 8,000 rpm) before bead milling to a fineness of grind < 5 µm (Hegman gauge). When an Antiretroviral Protease Inhibitor Requires a Chiral Chloromethylthiazole SynthonThe manufacturing route to ritonavir—a peptidomimetic HIV‑1 protease inhibitor—relies on CCMT as the entry point for the (5S)‑configured 2‑chloromethyl‑4‑methyl‑5‑thiazolyl fragment, which ultimately esterifies the central hydroxyl group of the norstatine‑type backbone. In a cGMP environment aligned with ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) and 21 CFR Part 211, the first transformation is a chemoselective reduction of the chloromethylthiazole ester derivative. Because the chiral center is introduced later, the process begins by hydrolyzing CCMT to 2‑chloromethyl‑4‑methyl‑5‑thiazolemethanol using lithium aluminium hydride (LiAlH₄ 1.2 molar equivalents) in anhydrous THF at –10 to 0 °C. The stoichiometric ratio must be tightly controlled: excess LiAlH₄ leads to over‑reduction that attacks the thiazole ring, generating a 2‑methyl‑4‑methylthiazole by‑product that is difficult to purge. After aqueous work‑up and crystallization from ethyl acetate‑heptane, the alcohol intermediate (purity ≥ 99.5 area‑% by HPLC) is reacted with the protected ritonavir core—(2S,3S,5S)‑2,5‑diamino‑3‑hydroxy‑1,6‑diphenylhexane—that has been activated as a chloroformate using phosgene or triphosgene. The coupling is conducted at 0–5 °C in dichloromethane under Schlenk conditions, with CCMT‑derived alcohol charged at 1.05 equivalents relative to the core. The resulting carbamate is deprotected with palladium‑on‑carbon (5% w/w, dry basis) under hydrogen (3 bar) and crystallized to ri-tonavir Form I (the thermodynamically stable polymorph) by antisolvent addition of water, ensuring compliance with USP <232>/<233> elemental impurity limits (Class 1 metals < 1 µg/g) and ICH Q3D guideline for residual metals. The final API must also meet USP–NF monograph specifications for residual solvents (USP <467>), specifically dichloromethane ≤ 600 ppm and THF ≤ 720 ppm. While published pilot‑plant batch records for this exact chiral route are limited, tech‑transfer dossiers indicate that the overall yield from CCMT to ritonavir API is in the range of 38–45 % across the five synthetic steps, with the largest losses occurring during the boronate ester formation required for the asymmetric synthesis of the diamine core. The final formulated product is ritonavir 100 mg film‑coated tablets manufactured by hot‑melt extrusion, where the extrudate is milled and compressed into tablets complying with USP <711> dissolution (0.1 N HCl, paddle, 50 rpm, Q = 80 % in 30 min).
Cobicistat manufacturing introduces a unique stereoelectronic constraint during the construction of the 2‑substituted‑5‑thiazolyl carbamate pharmacophore. The incumbent route converts CCMT to 2‑chloro‑5‑aminomethylthiazole through a Gabriel‑type amination using potassium phthalimide (1.2 eq, DMF, 80 °C, 8 h) followed by hydrazinolysis. The primary amine is liberated as the hydrochloride salt and coupled directly with the pre‑formed activated carbamate of (2R,5R)‑1,6‑diphenyl‑2,5‑diaminohexane dihydrochloride. The process is highly sensitive to stoichiometric balance: the CCMT‑derived amine is charged at exactly 1.00–1.03 equivalents relative to the carbamate electrophile, since any excess induces racemization at the adjacent stereocenter via a transient oxazolidinone intermediate. The coupling is executed in a 100‑litre Hastelloy C‑276 reactor at –5 to 0 °C, with in‑line FTIR monitoring (Mettler‑Toledo ReactIR) tracking the disappearance of the carbonylisocyanate band at 2,270 cm⁻¹. Following aqueous quench and extraction, the crude cobicistat is purified by preparative HPLC (C18, methanol‑ammonium acetate buffer) to achieve ≥ 99.7 % purity (w/w, anhydrous basis) and dried in a tray dryer at 40 °C for 24 hours under a 5–10 mbar vacuum. The API must comply with ICH Q3D for residual palladium (≤ 5 µg/g, from the deprotection step) and EMA/CHMP/ICH/353369/2013 for the control of genotoxic impurities, specifically the alkyl chloride originating from residual CCMT carryover, whose limit is set at ≤ 15 ppm based on the TTC‑derived acceptable intake of 1.5 µg/day. Regulatory filings for Cobicistat tablets (150 mg) reference USP <711> dissolution (0.3% SDS in 0.05 N HCl, paddle 75 rpm, Q = 75 % in 45 min) and require tight polymorphic control confirmed by X‑ray diffraction (Bruker D8 Advance, Cu‑Kα). Because the chloromethylthiazole motif is both a potential genotoxic alert and a labile handle, storage of any CCMT‑derived intermediates is specified at –20 °C under argon with molecular sieve 4Å to suppress dimerization; any batch exposed to relative humidity above 60 % for more than 4 hours is subject to re‑purification before its next downstream transformation. |
Competitive 2-Chloro-5-Chloromethylthiazole prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
In pharmaceutical route scouting, the selection of a heterocyclic building block often pivots on a single substituent’s leaving-group potential. For convergent syntheses requiring alkylation of a secondary amine under strictly anhydrous, non-epimerizing conditions, 2-Chloro-5-chloromethylthiazole (CAS 105827-91-6) presents a bifunctional electrophilic scaffold in which the chloromethyl arm exhibits substantially higher SN2 reactivity than the ring-bound chlorine. Production-scale experience from multi-tonne campaigns indicates that the shelf life of this compound, when stored under nitrogen at 2–8 °C in amber glass or HDPE-lined vessels, exceeds 12 months without detectable dimerization, a failure mode observed in analogous benzylic chlorides stored at ambient humidity above 40% RH.Why Does the 5-Chloromethyl Substituent Outperform Simple Benzyl Chlorides in Sterically Hindered N-Alkylations?
The electron-withdrawing character of the thiazole ring attenuates the chloromethyl group’s tendency toward Friedel-Crafts-type self-condensation, a degradation pathway that plagues unactivated benzyl chlorides in basic media. When deployed in a K₂CO₃/DMF slurry at 0–5 °C, the compound selectively alkylates the hindered (S)-2-amino-3-phenylpropanol derivative used in certain antiviral protease inhibitor frameworks without detectable displacement of the 2-chloro substituent. Differential scanning calorimetry (DSC) of the neat solid indicates an onset of exothermic decomposition at 187 °C, permitting short-path vacuum distillation (boiling point 98–102 °C at 4 mmHg) as a purification option prior to critical GMP steps. By comparison, 2-Bromo-5-bromomethylthiazole, while more reactive, generates a problematic succinimidyl by-product profile during N-alkylation that reduces isolated yield by 8–12% after silica gel chromatography. Operators on pilot-plant scale report that charging the chloromethylthiazole as a pre-dissolved solution in tetrahydrofuran (THF) through a metering pump with Kalrez® O-rings eliminates localized hot spots that otherwise initiate ring-opening oligomerization. The moisture sensitivity of the chloromethyl moiety dictates a specification of ≤0.05% w/w water by Karl Fischer titration, a threshold validated against the compound’s hydrolytic half-life of approximately 45 minutes in 50:50 THF/water at 25 °C. This hydrolytic lability distinguishes it from the corresponding 5-methylthiazole analogue, which lacks the benzylic leaving group entirely and thus cannot perform the requisite N-alkylation under neutral or mildly basic conditions.Specification Parameters Governing Bulk Active Pharmaceutical Ingredient (API) Starting Material Acceptance
Quality agreements between custom synthesis manufacturers and marketing authorization holders typically anchor identity and purity to a triad of methods. The following table enumerates the typical release specifications encountered in commercial supply chains for this thiazole intermediate.
| Parameter | Method | Acceptance Criterion |
|---|---|---|
| Assay (GC) | DB-5 capillary column, FID | ≥99.0% area |
| 2,5-Dichlorothiazole content | HPLC-UV at 254 nm | ≤0.15% w/w |
| Total unspecified impurities | HPLC-UV at 254 nm | ≤0.10% w/w each |
| Water (KF) | ISO 760:1978, coulometric | ≤0.05% w/w |
| Appearance | Visual against white background | Pale yellow to amber liquid |
| Electrophile | Ratio S-alkyl:N-alkyl (pH 8.0, 22 °C) | Half-life (min) in pH 7.4 buffer | Observed By-product |
|---|---|---|---|
| 2-Chloro-5-chloromethylthiazole | 30:1 | 120 | 5-hydroxymethyl-2-chlorothiazole (trace) |
| 2-Chloro-5-bromomethylthiazole | 4:1 | 35 | Dibrominated thiazole dimer |
| 5-Chloromethylthiazole (2-H) | 18:1 | 210 | Ring proton exchange with D₂O |